Shire's Vyvanse wins FDA nod as maintenance for pediatric ADHD

05/3/2013 | Medscape (free registration)

Shire obtained FDA approval to market Vyvanse, or lisdexamfetamine dimesylate, as maintenance therapy for children and teenagers with attention deficit hyperactivity disorder. This makes Vyvanse the only stimulant approved for use as a maintenance therapy in all ADHD patients older than 6, Shire says. The approval was based on data from a 32-week trial that showed lower treatment-failure rate among those who received Vyvanse.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC